Research ArticleResearch

Formulation, Development, and Evaluation of Floating Pulsatile Drug Delivery System of Atenolol

Swati C. Jagdale, Monali S. Sali, Ajay L. Barhate, Bhanudas S. Kuchekar and Aniruddha R. Chabukswar
PDA Journal of Pharmaceutical Science and Technology May 2013, 67 (3) 214-228; DOI: https://doi.org/10.5731/pdajpst.2013.00916

References

  1. 1.↵
    1. Lemmer B.
    Chronopharmacokinetics: implications for drug treatment. J. Pharm. Pharmacol. 1999, 51 (8), 887.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Kalantzi L. E,
    2. Karavas E.,
    3. Koutris E. X.,
    4. Bikiaris D. N.
    Recent advances in oral pulsatile drug delivery. Recent Pat. Drug Deliv. Formul. 2009, 3 (1), 49–63.
    OpenUrlPubMed
  3. 3.↵
    1. Singh B. N.
    Modified-release solid formulations for colonic delivery. Recent Pat. Drug Deliv. Formul. 2007, 1 (1), 53–63.
    OpenUrlPubMed
  4. 4.↵
    1. Ueda S.,
    2. Hata T.,
    3. Asakura S.,
    4. Yamaguchi H.,
    5. Ueda Y.
    Development of a novel drug release system, time controlled explosion system (TES). Part 1. Concept and design. J. Drug Target. 1994, 2 (1), 35–44.
    OpenUrlPubMed
  5. 5.↵
    1. Arvidson N. G.,
    2. Gudbjörnsson B.,
    3. Elfman L.,
    4. Rydén A. C.,
    5. Tötterman T. H.,
    6. Hällgren R.
    Circadian rhythm of secum interleucin-6 in rhematiod arthritis. Ann. Rheum. Dis. 1994, 53 (8), 521–524.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Barnes J. P.
    Circadian variation in airway function. Am. J. Med. 1985, 79 (6A), 5–9.
    OpenUrlPubMed
  7. 7.↵
    1. Fox K. M.,
    2. Mulcahy D. A.
    Circadian rhythms in cardiovascular diseases. Postgrad. Med. J. 1991, 67, S33–S36.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Millar-Craig M. W.,
    2. Bishop C. N.,
    3. Raftery E. B.
    Circadian variation of blood pressure. Lancet 1978, 1 (8068), 795–797.
    OpenUrlPubMedWeb of Science
  9. 9.↵
    1. McTavish D.,
    2. Sorkin E. M.
    Verapamil: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension. Drugs 1989, 38, 19–76.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Bussemer T.,
    2. Dashevsky A.,
    3. Bodmeier R.
    A pulsatile drug delivery system based on rupturable coated hard gelatin capsules. J. Controlled Release 2003, 93 (3), 331–339.
    OpenUrlPubMed
  11. 11.↵
    1. Bussemer T.,
    2. Peppas N. A.,
    3. Bodmeier R.
    Evaluation of the swelling, hydration and rupturing properties of the swelling layer of a rupturable pulsatile drug delivery system. Eur. J. Pharm. Biopharm. 2003, 56 (2), 261–270.
    OpenUrlPubMed
  12. 12.↵
    1. Dashevsky A.,
    2. Mohamad A.
    Development of pulsatile multiparticulate drug delivery system coated with aqueous dispersion Aquacoat ECD. Eur. J. Pharm. Biopharm. 2006, 318 (1–2), 124–131.
    OpenUrl
  13. 13.↵
    1. Karavas E.,
    2. Georgarakis E.,
    3. Bikiaris D.
    Application of PVP/HPMC miscible blends with enhanced mucoadhesive properties for adjusting drug release in predictable pulsatile chronotherapeutics. Eur. J. Pharm. Biopharm. 2006, 64 (1), 115–126.
    OpenUrlPubMed
  14. 14.↵
    1. Magruder P. R.,
    2. Barclay B.,
    3. Wong P. S. L.,
    4. Theeuwes F.
    Composition Comprising Salbutamol, U.S. Patent 4,751,071, 1988.
  15. 15.↵
    1. Cutler N.,
    2. Anders R.,
    3. Stanford S.,
    4. Stramed J.,
    5. Awan N.,
    6. Bultas J.,
    7. Lahari A.,
    8. Woroszylska M.
    Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris. Am. J. Cardiol. 1995, 75 (16), 1102–1106.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Conte U.,
    2. Colombo P.,
    3. La Manna A.,
    4. Gazzaniga A.,
    5. Sangalli M. E.,
    6. Giuchedi P.
    A new ibuprofen pulsed release oral dosage form. Drug Dev. Ind. Pharm. 1989, 15 (14–16), 2583–2596.
    OpenUrl
  17. 17.↵
    1. Conte U.,
    2. Maggi L.,
    3. Torre M. L.,
    4. Giunchedi P.,
    5. La Manna A.
    Press-coated tablets for time-programmed release of drugs. Biomaterials 1993, 14 (13), 1017–1023.
    OpenUrlPubMed
  18. 18.↵
    1. Conte U.,
    2. Maggi L.
    Modulation of the dissolution profiles from Geomatrix multi-layer matrix tablets containing drug of different solubility. Biomaterials 1996, 17 (9), 889–896.
    OpenUrlPubMed
  19. 19.↵
    1. Hedben J.,
    2. Wilson C.,
    3. Spiller R.,
    4. Gilchrist P.,
    5. Blackshaw E.,
    6. Frier M.,
    7. Perkins A.
    Regional differences in quinine absorption from the undisturbed human colon assessed using a timed release delivery system. Pharm. Res. 1999, 16 (7), 1087–1092.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Ghika J.,
    2. Gashoud J. P.,
    3. Gasser U.
    Clinical efficacy and tolerability of a new levodopa/benserazide dual-release formulation in parkinsonian patients. Clin. Neuropharmacol. 1997, 20 (2), 130–139.
    OpenUrlPubMed
  21. 21.↵
    1. Sharma S.,
    2. Pawar A.
    Low density multiparticulate system for pulsatile release of meloxicam. Int. J. Pharm. 2006, 313 (1–2), 189–197.
    OpenUrlPubMed
  22. 22.↵
    1. Li S.,
    2. Daggy B. P.,
    3. Mirchandani H. L.,
    4. Chien Y. W.
    Effect of HPMC and carbopol on the release and floating properties of gastric floating drug delivery system using factorial design. Int. J. Pharm. 2003, 253 (1–2), 13–22.
    OpenUrlPubMed
  23. 23.↵
    1. Khanna R.,
    2. Agarwal S. P.,
    3. Ahuja A.
    Muco-adhesive buccal tablets of clotrimazole for oral candidiasis. Drug Dev. Ind. Pharm. 1997, 23 (8), 831–837.
    OpenUrl
  24. 24.↵
    1. Singh B. N.,
    2. Kim K. H.
    Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J. Controlled Release 2000, 63 (3), 235–259.
    OpenUrlPubMed
  25. 25.↵
    1. Arora S.,
    2. Ali J.,
    3. Ahuja A.,
    4. Khar R. K.,
    5. Baboota S.
    Floating drug delivery systems: a review. AAPS PharmSciTech 2005, 6 (3), E372–E390.
    OpenUrlPubMed
  26. 26.↵
    1. Baumgartner S.,
    2. Kristl J.,
    3. Vrecer F.,
    4. Vodopivec P.,
    5. Zorko B.
    Optimisation of floating matrix tablets and evaluation of their gastric residence time. Int. J. Pharm. 2000, 195 (1–2), 125–135.
    OpenUrlPubMed
  27. 27.↵
    1. Satwara R. S.,
    2. Patel P. K.
    Formulation and optimization of chronomodulated press-coated tablet of carvedilol by Box–Behnken statistical design. ChronoPhysiology and Therapy 2012, 2 (1), 35–50.
    OpenUrl
  28. 28.↵
    1. Zilpe C. R.,
    2. Dhumale A. J.,
    3. Gudalwar B. R.,
    4. Kawtikwar P. S.,
    5. Sakarkar D. M.
    Development and evaluation of pulsatile press coated tablet to control early morning BP surge. Int. J. Pharm. World Res. 2012, 3 (2), 1–19.
    OpenUrl
  29. 29.↵
    1. Sibel B. P.,
    2. Suba B. R.,
    3. Vural I.,
    4. Unlu N.,
    5. Capan Y.
    Evaluation of drug-excipient interaction in the formulation of celecoxib tablets. Acta Poloniae Pharmaceutica Drug Res. 2011, 68 (3), 423–433.
    OpenUrl
  30. 30.↵
    1. Moon A.,
    2. Kondawar M.,
    3. Shah R.
    Formulation and evaluation of press-coated indomethacin tablets for pulsatile drug delivery system. J. Pharm. Res. 2011, 4 (3), 564–566.
    OpenUrl
Back to top

In This Issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Formulation, Development, and Evaluation of Floating Pulsatile Drug Delivery System of Atenolol
Swati C. Jagdale, Monali S. Sali, Ajay L. Barhate, Bhanudas S. Kuchekar, Aniruddha R. Chabukswar
PDA Journal of Pharmaceutical Science and Technology May 2013, 67 (3) 214-228; DOI: 10.5731/pdajpst.2013.00916
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords